ArticleEye (London, England)2026
Outcomes on pseudophakic mini-monovision with monofocal intraocular lens on intermediate vision with immediate sequential bilateral cataract surgery.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate visual, refractive and patient-reported outcomes of a mini-monovision strategy using the Clareon® (Alcon Laboratories, Fort Worth, Texas, USA) monofocal intraocular lens (IOL) for intermediate vision following immediate sequential bilateral cataract surgery (ISBCS).
methodsIn this prospective study, twenty-seven patients (54 eyes) underwent ISBCS with Clareon® monofocal IOL implantation, targeting emmetropia in the dominant eye and -0.75 D myopic offset in the non-dominant eye. The primary outcome was binocular uncorrected intermediate visual acuity (UCIVA) at 66 cm at 1 and 3 months. Secondary outcomes included monocular UCIVA, binocular uncorrected distance visual acuity (UCDVA) and best-corrected distance visual acuity (BCDVA). Tertiary outcomes were binocular defocus curve, reading speed (Salzburg Reading Desk) and Catquest-9SF questionnaire.
resultsMean participant age was 73.5 years (range 53-91), with 59% female. Binocular UCIVA was 0.11 ± 0.14 and 0.10 ± 0.12 LogMAR ( ± SD) at 1 and 3 months, respectively. Monocular UCIVA (non-dominant eye) was 0.14 ± 0.16 and 0.11 ± 0.13 LogMAR. Binocular UCDVA was -0.01 ± 0.10 and -0.02 ± 0.10 LogMAR at 1 and 3 months. Binocular BCDVA was -0.07 ± 0.10 and -0.07 ± 0.07 LogMAR. Reading speed improved from 99 ± 32 to 103 ± 39 words per minute. Defocus curves demonstrated visual acuity of 0.1 LogMAR or better from -1.50 D to +0.50 D. Refractive outcomes were stable with a mean spherical equivalent of +0.08 ± 0.30D (dominant eye) and -0.66 ± 0.25D (non-dominant eye) at three months. Catquest-9SF Rasch scores improved from 0.28 ± 1.62 preoperatively to 2.48 ± 1.10 at 1 month and 2.62 ± 1.24 at 3 months (both p < 0.01).
conclusionsMini-monovision with Clareon® monofocal IOLs and ISBCS provides good binocular uncorrected intermediate vision with high patient satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.